Cardiovasc Diabetol: Role of continuous glucose monitoring in patients with high-risk cardiovascular diabetes

Background: Blood glucose self-monitoring (SMBG) has so far been the most widely used method for people with diabetes to assess their own blood glucose levels and guide diabetes treatment

The Continuous Glucose Monitoring (CGM) device measures the concentration

Notably, recently published randomized clinical trials (RCTs) have shown improved cardiovascular (CV) outcomes in diabetic patients treated with a number of new antihyperglycemic drugs, which has increased cardiologists' interest in appropriate treatment of diabetes and stimulated a new relationship

Purpose: With this background in mind, the purpose of this study was to conduct a Delphi survey in a team of Italian diabetologists and cardiologists to gather expert consensus

Methods: 22 claims were made regarding the types of patients who could benefit from CGM, the prognostic effect of CGM on patients with diabetes mellitus and heart disease, the use of CGM during acute cardiovascular events, and the educational issues

Results: 40 experts (95%) answered the survey

Figure 1 Delphi process description

Figure 2 Geographical distribution of respondents

Table 1 Respondents' clinical experience and professional roles

The degree of consistency of the statements in table 2

Conclusion: According to this Delphi consensus, the clinical and prognostic application of CGM in patients with high-risk cardiovascular diabetes is promising and deserves specialized research to confirm expert feelings

Di Mario C, Genovese S, Lanza GA,Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus.